An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder

Annals of Pharmacotherapy

Volumn 43, Issue 6, 2009, Pages 1084-1095

  Chavez, Benjamin ^a,d   Sopko Jr , Michael A ^b   Ehret, Megan J ^c   Paulino, Raphael E ^a   Goldberg, Kyle R ^a   Angstadt, Kristine ^a   Bogart, Gregory T ^a  

^a RUTGERS UNIVERSITY   (United States)

^b TOURO COLLEGE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d MONMOUTH MEDICAL CENTER   (United States)

Author keywords

Amphetamine; Attention deficit hyperactivity disorder; Central nervous system stimulants; Methylphenidate

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LIQUADD; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; APPETITE; APPLICATION SITE REACTION; ATTENTION DEFICIT DISORDER; BIOEQUIVALENCE; BLOOD LEVEL; BLOOD PRESSURE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYING; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EMOTIONAL DISORDER; GROWTH INHIBITION; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LIPID DIET; LOW DRUG DOSE; MORNING DOSAGE; NIGHTMARE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PSYCHOSIS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; TIC; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADOLESCENT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSAGE FORMS; HUMANS; METHYLPHENIDATE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 67249160091     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L523     Document Type: Review

References (48)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rhode LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-948 (Pubitemid 46972911)
2. Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med 2007;161:857-864 (Pubitemid 47360887)
3. Steinhoff KW. Special issues in the diagnosis and treatment of ADHD in adolescents. Postgrad Med 2008;120:60-68
4. Diagnostic and statistical manual of mental disorders. 4th ed. Text-revision. Arlington, VA: American Psychiatric Association, 2000.
5. Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 2007;32:631-642 (Pubitemid 47356045)
6. Rappley MD. Clinical practice: attention-deficit/hyperactivity disorder. N Engl J Med 2005;352:165-173
7. American Academy of Pediatrics. Subcommittee on attention-deficit/ hyperactivity disorder and committee on quality improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001;108:1033-1044
8. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006;13:e50-e62. (Pubitemid 46165597)
9. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attentiondeficit/ hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90. (Pubitemid 43042140)
10. Maia CRM, Matte BC, Ludwig HT, Rohde LA. Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2008;17:133-142
11. Sonuga-Barke EJS, Coghill D, Markowitz J, Swanson J, Vandenberghe M, Hatch S. Sex differences in the pharmacodynamics of ADHD children's response to methylphenidate: a comparison of two formulations. J Am Acad Child Adolesc Psychiatry 2007;46:701-710 (Pubitemid 46816823)
12. Sonuga-Barke EJS, Lier P, Swanson J, et al. Heterogenicity in the pharmacodynamics of two long acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2008;17:245-254
13. Pelham WE Jr., Manos MJ, Ezzell CE, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:522-529 (Pubitemid 40720951)
14. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylpheniate transdermal system in children with ADHD. J Atten Disord 2006;9:476-485 (Pubitemid 43171141)
15. Wilens TE, Boellner SW, Lopez FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008;47:700-708
16. Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:149-159 (Pubitemid 351282009)
17. Greenhil LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H. Efficacy and safety of dexmethylphenidate extended-release capsule in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:817-823 (Pubitemid 43932908)
18. Silva RR, Muniz R, Pestreich L, et al. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008;47:199-208. (Pubitemid 351158788)
19. Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A. Treatment of children with attention deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d,l methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bull 2008;41:19-33.
20. Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R. Efficacy and safety of extended-release dexmethylphenidate compared with d,lmethylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 2008;18:248-256
21. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disorder 2005;9:275-289 (Pubitemid 41551759)
22. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:266-279
23. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007;29:450-463 (Pubitemid 46924786)
24. Biederman J, Boellner SW, Childress A, Lopez FA, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-976 (Pubitemid 47562371)
25. Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatric Clin North Am 2006;15:13-50. (Pubitemid 41735237)
26. Abikoff H, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004;43:802-811 (Pubitemid 38808485)
27. McDonagh MS, Peterson K, Dana T, Thakurta S. Drug class review on pharmacologic treatments for ADHD. 2007. www.ohsu.edu/drugeffectiveness/reports/ final.cfm (accessed 2008 Aug 6).
28. Orange book. Rockwille, MD: Food and Drug Administration, 2008. www.fda.gov/cder/orange/default.htm (accessed 2008 Oct 24).
29. Yonezawa Y, Ishida S, Sunada H. Release from or through a wax matrix system. VI. Analysis and prediction of the entire release process of the wax matrix tablet. Chem Pharm Bull 2005;53:915-918
30. Product information. Concerta (methylphenidate osmotic release oral system). Mountain View, CA: ALZA Corporation, June 2008.
31. Elan Corporation. Dublin; SODAS. 2001-2004. www.elan.com/edt/drug- optimization/sodas.asp (accessed 2008 Aug 3).
32. Product information. Ritalin LA (methylphenidate). East Hanover, NJ: Novartis Pharmaceutical Corporation, April 2007.
33. Product information. Metadate CD (methylphenidate). Smyrna, GA: UCB Pharma Inc., February 2007.
34. Arnold LE, Lindsay RL Lopez FA, et al. Treating attention-deficit/ hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007;120:1100-1106 DOI 10.1542/peds.2007-0542 (Pubitemid 350085550)
35. Kalia YN, Merino V, Guy RH. Transdermal drug delivery: clinical aspects. Dermatol Clin 1998;16:289-299 (Pubitemid 28205025)
36. Gonzalez MA, Pentikis HS, Campbell DA, Chin M, Duchin K. Methylphenidate (MPH) steady-state pharmacokinetics with a once-daily transdermal system. Presented at: Annual meeting of the American Association of Pharmaceutical Scientists, November 10-14, 2002, Toronto, Ontario, Canada.
37. Srinivas NR, Hubbard JW, Quinn D, Middha KK. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention-deficit hyperactivity disorder. Clin Pharmacol Ther 1992;52:561-568
38. Product information. Focalin XR (dexmethylphenidate). East Hanover, NJ: Novartis Pharmaceuticals, April 2007.
39. Wilens TE. Mechanism of action of agents used in attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2006;67(suppl 8):32-37 (Pubitemid 44389276)
40. Manos MJ, Short EJ, Findling RL. Differential effectiveness of methylphenidate and Adderall (R) in school-age youths with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38:813-819 (Pubitemid 29309840)
41. Product information. Adderall XR (mixed amphetamine salts). Wayne, PA: Shire US Incorporated, March 2007.
42. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41:26S-49S.
43. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997;100:662-666 (Pubitemid 27425991)
44. Efron D, Jarman F, Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial (abstract). Pediatrics 1997;100:1025.
45. Product information. Vyvanse (lisdexamfetamine) Wayne, PA: Shire US Incorporated, April 2008.
46. Lopez FA, Ginsberg LD, Arnold V. Effects of lisdexamfetamine on parentrated measures in children aged 6 to 12 years with attention-deficit/ hyperactivity disorder: a secondary analysis. Postgrad Med 2008;120:89-102.
47. Blick SK, Keating GM. Lisdexamfetamine. Pediatr Drugs 2007;9:129-135
48. Jasinski D, Krishnan S. A double-blind, randomized, placebo-and active- controlled, 6-period crossover study to evaluate the likability, safety, and abuse potential of lisdexamfetamine dimesylate (LDX) in adult stimulant abusers (poster). 2006 US Psychiatric & Mental Health Congress, November 18, 2006, New Orleans, LA.